World Drug and Medication: Throat Cancer – Pipeline Review, H1 2012

• Publication date: April 2012

This report provides data on the therapeutic development for Throat Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Throat Cancer. 'Throat Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor p...

This report provides data on the therapeutic development for Throat Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Throat Cancer. 'Throat Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for Throat Cancer.
- A review of the Throat Cancer products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Throat Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Throat Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Throat Cancer pipeline depth and focus of Throat Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Drug And Medication Industry

Table of Contents
Data table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global March kets Direct Report Coverage 8
Throat Cancer Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Throat Cancer 10
Throat Cancer Therapeutics under Development by Firms 12
Throat Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Throat Cancer Therapeutics – Products under Development by Firms 21
Throat Cancer Therapeutics – Products under Investigation by Universities/Institutes 22
Companies Involved in Throat Cancer Therapeutics Development 28
F. Hoffmann-La Roche Ltd. 28
YM BioSciences Inc. 29
Cyclacel Pharmaceuticals Inc. 30
Jiangsu Hengrui Medicine Co., Ltd. 31
Biotech Pharmaceuticals Co., Ltd. 32
Throat Cancer – Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
Seliciclib - Drug Profile 39
Cisplatin + Radiation Therapy - Drug Profile 41
HPPH - Drug Profile 42
Vorinostat + Capecitabine - Drug Profile 44
Cetuximab + Cisplatin + Radiotherapy - Drug Profile 46
Cisplatinum + Radiotherapy - Drug Profile 48
Xeloda + Oxaliplatin - Drug Profile 50
5-Fluorouracil + Hydroxyurea + Bevacizumab + Radiation Therapy - Drug Profile 52
Gemcitabine + Cisplatin + Radiation Therapy - Drug Profile 54
Cisplatin + Radiation Therapy1 - Drug Profile 55
Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 56
Cisplatin + Xeloda + Radiation Therapy - Drug Profile 58
Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 60
GW786034 - Drug Profile 62
Gemcitabine + Cisplatinn - Drug Profile 63
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 64
Cetuximab + Radiation Therapy - Drug Profile 66
Carboplatin + Paclitaxel - Drug Profile 67
Fludarabine + Radiation Therapy - Drug Profile 69
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 70
Radiation Therapy + Cetuximab - Drug Profile 71
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 73
Docetaxel + Cisplatin - Drug Profile 75
Bevacizumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 77
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 79
Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 81
Radiotherapy + Cisplatin + Fluorouracil - Drug Profile 83
Docetaxel + Cisplatin + Fluorouracil - Drug Profile 85
Celecoxib - Drug Profile 87
Cisplatin + Erlotinib Hydrochloride + Radiation Therapy - Drug Profile 88
TheraCIM - Drug Profile 90
Vorinostat + Cisplatin + Radiation Therapy - Drug Profile 92
Gemcitabine + Carboplatin - Drug Profile 93
Velcade - Drug Profile 95
Carboplatin + Cisplatin + Docetaxel + Fluorouracil + Lapatinib + Radiation Therapy - Drug Profile 96
Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 99
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile 101
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 103
Foscan - Drug Profile 104
Docetaxel + Cisplatin + 5-Fluorouracil + Radiotherapy - Drug Profile 105
TS-1 + Nedaplatin + Radiation Therapy - Drug Profile 107
Cisplatin + 5-Fluorouracil + Celecoxib + Radiation Therapy - Drug Profile 108
S-1 + Radiation Therapy - Drug Profile 110
Cisplatin + Radiation Therapy - Drug Profile 111
Docetaxel + Radiation Therapy - Drug Profile 112
S-1 + Radiation Therapy - Drug Profile 114
Minocycline - Drug Profile 116
Docetaxel + 5-Fluorouracil + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 117
Mitomycin C + Epirubicin + Cisplatin + 5-Fluorouracil + Leucovorin - Drug Profile 119
Docetaxel + Radiation Therapy - Drug Profile 121
Carbogen + Nicotinamide + Radiotherapy - Drug Profile 122
Cisplatin + Intensity-Modulated Radiation Therapy - Drug Profile 123
Cisplatin + Fluorouracil + Docetaxel + Cetuximab - Drug Profile 125
Cisplatin + Cytochlor + Tetrahydrouridine + Radiation Therapy - Drug Profile 127
Cisplatinum + Fluorouracil + Radiotherapy - Drug Profile 129
Recombinant Epstein-Barr Virus (EBV) Vaccine - Drug Profile 131
Cisplatin + Cetuximab + 5-Fluorouracil + Taxotere + Radiation Therapy - Drug Profile 132
5-Fluorouracil + Cisplatin + Radiation Therapy - Drug Profile 134
Interleukin + NK Cells - Drug Profile 135
Cetuximab + Docetaxel + Cisplatin + 5-FU - Drug Profile 136
Paclitaxel + Carboplatin + Cisplatin + Amifostine Trihydrate + Radiation Therapy - Drug Profile 138
Panitumumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 140
Bevacizumab + Cisplatin + Fluorouracil - Drug Profile 142
Cetuximab + Cisplatin + Docetaxel + 5-FU - Drug Profile 144
Cetuximab + Cisplatin + Radiation Therapyy - Drug Profile 146
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile 148
Cisplatin + Radiation Therapy - Drug Profile 150
Adriamycin + Lomustine - Drug Profile 151
Erbitux + Docetaxel + Cisplatin - Drug Profile 152
Amifostine + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 154
Cisplatin + Paclitaxel + Radiation Therapy - Drug Profile 156
Lapatinib Ditosylate + Capecitabine - Drug Profile 157
Taxotere + Cisplatin + 5-FU - Drug Profile 159
Cisplatin + Radiation Therapy - Drug Profile 161
Erbitux + Radiation Therapy - Drug Profile 162
Taxotere + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 163
Docetaxel + Cisplatin + 5-Fluorouracil + Erbitux + Radiation Therapy - Drug Profile 165
Docetaxel + Cisplatin + Fluorouracil + Carboplatin + Cetuximab + Radiation Therapy - Drug Profile 167
Nedaplatin + Radiation Therapy - Drug Profile 169
Modified Vaccinia Ankara Vaccine - Drug Profile 170
Axitinib - Drug Profile 171
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 172
Docetaxel + Cisplatin + 5-Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile 174
Sunitinib + Cisplatin + Gemcitabine - Drug Profile 176
Docetaxel + Cisplatin + Fluorouracil + Cetuximab + Radiation Therapy - Drug Profile 178
VTX-2337 + Cetuximab - Drug Profile 180
Nimotuzumab + Cisplatin + Radiation Therapy - Drug Profile 182
LBH589 + RAD001 - Drug Profile 183
S-1 + Radiation Therapy - Drug Profile 184
MK2206 - Drug Profile 185
Cisplatin + Radiation Therapy - Drug Profile 186
Famitinib - Drug Profile 187
SOX - Drug Profile 188
MK-2206 - Drug Profile 189
Docetaxel + Cisplatin + Radiation Therapy - Drug Profile 190
Famitinib + Cisplatin + Radiation Therapy - Drug Profile 192
Throat Cancer Therapeutics – Drug Profile Updates 194
Throat Cancer Therapeutics – Discontinued Products 197
Throat Cancer Therapeutics - Dormant Products 198
Throat Cancer – Product Development Milestones 202
Featured News & Press Releases 202
Appendix 207
Methodology 207
Coverage 207
Secondary Research 207
Primary Research 207
Expert Panel Validation 207
Contact Us 208
Disclaimer 208

List of Tables

Number of Products Under Development for Throat Cancer, H1 2012 16
Products under Development for Throat Cancer – Comparative Analysis, H1 2012 17
Number of Products under Development by Firms, H1 2012 18
Number of Products under Investigation by Universities/Institutes, H1 2012 20
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 21
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 22
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 23
Comparative Analysis by Late Stage Development, H1 2012 24
Comparative Analysis by Mid Clinical Stage Development, H1 2012 25
Comparative Analysis by Early Clinical Stage Development, H1 2012 26
Products under Development by Firms, H1 2012 27
Products under Investigation by Universities/Institutes, H1 2012 28
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 29
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 30
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 31
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 32
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 33
F. Hoffmann-La Roche Ltd., H1 2012 34
YM BioSciences Inc., H1 2012 35
Cyclacel Pharmaceuticals Inc., H1 2012 36
Jiangsu Hengrui Medicine Co., Ltd., H1 2012 37
Biotech Pharmaceuticals Co., Ltd., H1 2012 38
Assessment by Monotherapy Products, H1 2012 39
Assessment by Combination Products, H1 2012 40
Assessment by Stage and Route of Administration, H1 2012 42
Assessment by Stage and Molecule Type, H1 2012 44
Throat Cancer Therapeutics – Drug Profile Updates 200
Throat Cancer Therapeutics – Discontinued Products 203
Throat Cancer Therapeutics – Dormant Products 204
Throat Cancer Therapeutics – Dormant Products (Contd..1) 205
Throat Cancer Therapeutics – Dormant Products (Contd..2) 206
Throat Cancer Therapeutics – Dormant Products (Contd..3) 207

List of Figures

Number of Products under Development for Throat Cancer, H1 2012 16
Products under Development for Throat Cancer – Comparative Analysis, H1 2012 17
Products under Development by Firms, H1 2012 18
Products under Investigation by Universities/Institutes, H1 2012 19
Late Stage Products, H1 2012 24
Mid Clinical Stage Products, H1 2012 25
Early Clinical Stage Products, H1 2012 26
Assessment by Monotherapy Products, H1 2012 39
Assessment by Combination Products, H1 2012 40
Assessment by Route of Administration, H1 2012 41
Assessment by Stage and Route of Administration, H1 2012 42
Assessment by Molecule Type, H1 2012 43
Assessment by Stage and Molecule Type, H1 2012 44